Loading clinical trials...
Loading clinical trials...
A Phase 1, Dose Escalation, Double Blind, Placebo Controlled Clinical Trial With Controlled Human Malaria Infections (CHMI) to Evaluate Safety, Tolerability, Pharmacokinetics, and Protective Efficacy of an Anti-Malaria Human Monoclonal Antibody, MAM01, in Healthy, Malaria-Naive Adults
Conditions
Interventions
MAM01 1.5 mg/kg
Placebo
+9 more
Locations
1
United States
Center for Vaccine Development and Global Health, 685 W. Baltimore Street
Baltimore, Maryland, United States
Start Date
August 14, 2023
Primary Completion Date
December 13, 2024
Completion Date
December 13, 2024
Last Updated
February 19, 2025
NCT07074665
NCT06967519
NCT07269314
NCT05690841
NCT06854042
NCT02471378
Lead Sponsor
Gates Medical Research Institute
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions